




公告日期	2026/8/18
異動類別	藥品變更
異動原因	包裝變更
異動描述	Apremilast 30mg/tab (Otezla®)歐泰樂膜衣錠廠商來文，自批號1191769起，鋁箔包裝之單顆藥錠標示方式由「劑量」變更為「中文品名及劑量」，並更新仿單內容，藥品包裝變更。 舊品用罄，啟用新品。

異動內容		
	舊藥品	新藥品
料號	083327	
學名	Apremilast	
商品名	Otezla	
中文名	歐泰樂膜衣錠	
主成份及含量	30mg/tab	
製造廠名稱	Patheon Inc (Patheon)	
產地	加拿大	
健保代碼	BC27211100	
外觀/圖檔		
用法	口服	

小孩劑量	Psoriasis, plaque (moderate to severe): Children ≥6 years and Adolescents: Weight 20 to <50 kg: Day 1: Immediate release (Otezla): Oral: 10 mg once daily in the morning. Day 2: Immediate release (Otezla): Oral: 10 mg twice daily. Day 3: Immediate release (Otezla): Oral: 10 mg in the morning and 20 mg in the evening. Day 4 and thereafter: Immediate release (Otezla): Oral: 20 mg twice daily. Weight ≥50 kg: Day 1: Immediate release (Otezla): Oral: 10 mg once daily in the morning. Day 2: Immediate release (Otezla): Oral: 10 mg twice daily. Day 3: Immediate release (Otezla): Oral: 10 mg in the morning and 20 mg in the evening. Day 4: Immediate release (Otezla): Oral: 20 mg twice daily. Day 5: Immediate release (Otezla): Oral: 20 mg in the morning and 30 mg in the evening. Day 6 and thereafter: Immediate release (Otezla): Oral: 30 mg twice daily.
成人劑量	Behcet disease, psoriasis, or psoriatic arthritis: Oral: Initial: 10 mg in the morning on day 1. Titrate upward by additional 10 mg per day on days 2 to 5 as follows: Day 2: 10 mg twice daily; Day 3: 10 mg in the morning and 20 mg in the evening; Day 4: 20 mg twice daily; Day 5: 20 mg in the morning and 30 mg in the evening. Maintenance dose: 30 mg twice daily starting on day 6.
副作用	